Turk Ilac ve SerumnayiIST:TRILC -1.69%61 Pretax Margin % is 17.67% as of Sep. 2025, which is 314% above its 10-year median of 4.27. GuruFocus rates IST:TRILC with a GF Score™ of 61/100 and a GF Value™ of ₺3.60 (Possible Value Trap). The stock has 11 warning signs investors should review. Among 954 Drug Manufacturers companies, Turk Ilac ve Serumnayi ranks worse than 75.37% on this metric.
The historical rank and industry rank for Turk Ilac ve Serumnayi's Pretax Margin % or its related term are showing as below:
IST:TRILC'
s Pretax Margin % Range Over the Past 10 Years
Min: -8.14 Med: 4.27 Max: 20.18
Current: -8.14
IST:TRILC's Pretax Margin % is ranked worse than 75.37% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs IST:TRILC: -8.14
Turk Ilac ve Serumnayi (IST:TRILC) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Turk Ilac ve Serumnayi Pretax Margin % Related Terms
Turk Ilac ve Serumnayi Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Turk Ilac ve Serumnayi's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IST:TRILC vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Turk Ilac ve Serumnayi's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Turk Ilac ve Serumnayi Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Turk Ilac ve Serumnayi's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Turk Ilac ve Serumnayi's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Turk Ilac ve Serumnayi (IST:TRILC) has a Pretax Margin % of 17.67% as of Sep. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Turk Ilac ve Serumnayi and its competitors. This is 314% above median its historical median of 4.27. According to the industry distribution chart, Turk Ilac ve Serumnayi ranks #719 out of 954 companies in the Drug Manufacturers industry, placing it in the top 75.4%.
Is Turk Ilac ve Serumnayi's Pretax Margin % too high?
Turk Ilac ve Serumnayi's current Pretax Margin % of 17.67% is 314% above median its 10-year median of 4.27. The Drug Manufacturers industry median Pretax Margin % is 7.30. Turk Ilac ve Serumnayi's value of 17.67% is 142.2% above this industry median. Based on the distribution chart, Turk Ilac ve Serumnayi ranks #719 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Turk Ilac ve Serumnayi has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Turk Ilac ve Serumnayi's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Turk Ilac ve Serumnayi ranks #719 out of 954 companies for Pretax Margin %. This places Turk Ilac ve Serumnayi in the lower half of its industry. The industry median Pretax Margin % is 7.30. Turk Ilac ve Serumnayi's value of 17.67% is 142.2% above this benchmark. While the company's 10-year median is 4.27 vs. the industry median of 7.30, Turk Ilac ve Serumnayi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Turk Ilac ve Serumnayi's current Pretax Margin % of 17.67% is 142.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Turk Ilac ve Serumnayi and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Turk Ilac ve Serumnayi's current Pretax Margin % is 17.67%, which is 314% above median its own 10-year median of 4.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turk Ilac ve Serumnayi stock overvalued right now?
Based on GuruFocus' analysis, Turk Ilac ve Serumnayi (IST:TRILC) is currently considered Possible Value Trap. The stock's GF Value™ is ₺3.60, compared to a current price of ₺1.16 — trading 67.8% below its estimated fair value. The current Pretax Margin % is 17.67%, which is 314% above median its 10-year median of 4.27 and 142.2% above the Drug Manufacturers industry median of 7.30. Turk Ilac ve Serumnayi's overall GF Score™ is 61/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Turk Ilac ve Serumnayi (IST:TRILC), the current Pretax Margin % is 17.67% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Turk Ilac ve Serumnayi (IST:TRILC) Overvalued in 2026?
Based on GuruFocus' analysis, Turk Ilac ve Serumnayi stock appears to be undervalued.
The current stock price of ₺1.16 is trading 67.8% below its estimated GF Value™ of ₺3.60.
GuruFocus considers Turk Ilac ve Serumnayi to be Possible Value Trap.
Key valuation signals for IST:TRILC:
Pretax Margin %: 17.67% (314% above median its 10-year median of 4.27)
GF Value™: ₺3.60 vs. price of ₺1.16 (67.8% below fair value)
Industry Position: 142.2% above the Drug Manufacturers median (#719 of 954)
No single metric tells the full story. See the IST:TRILC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:TRILC has been successfully added to your 
